InformationClinical trials have complex eligibility criteria.
Always talk to your clinician about you’re interest in participating in a trial.
Learn why

Optimise reading forHealth ProfessionalsPatients

RecruitingLast updated: 19 January 2024

WU-NK-101: This study is aims to determine the recommended dose level, safety and effectiveness of a new drug (called WU-NK-101) in people with relapsed or refractory acute myeloid leukaemiaA Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)

Clinical summary


This study consists of two phases: dose escalation and dose expanion. 

During the dose escalation phase, up to 18 participants will be treated with WU-NK-101 in up to 3 Dose Levels (DL) until maximum tolerated dose (MTD) or maximum administered dose (MAD) is determined.

Once the MTD/MAD is defined, 6 additional participants will be enrolled in the Cohort Expansion Phase to durther study the safety and tolerability, as well as determine the recommended phase 2 dose (RP2D) of WU-NK-101. Participants in the COhort Expansion Phase, who achieve a partial response (PR), may receive up to 2 further re-induction cycles contigent on safety in the Dose Escalation Phase; participants who achieve a complete remission with partial haematologic recovery (CRh) or complete remission with incomplete haematologic recovery (CRi) at any point during the course of treatment may receive a further consolidation cycle, for a total of up to 4 cycles per patient. During cohort expansion, dosing breaks of up to two weeks are allowed between cycles.

WU-NK-101 will be administered on Day 1, Day 8 and Day 15 of each 28-day cycle.


This trial is treating patients with acute myeloid leukaemia


Blood Cancers Haematological





Trial Acronym


More information

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Trial sponsor

Wugen, Inc.

Scientific Title

A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)



  1. Confirmed diagnosis of primary or secondary AML (any subtype except acute promyelocytic leukemia) according to World Health Organization (WHO) 2016 classification
  2. Unlikely to benefit from standard of care therapy defined by any one of the following criteria:

    1. Primary induction failure (PIF) defined as leukemia refractory to ≥ 1 induction attempts. Induction attempts include 1 high-dose and/or 2 standard-dose cytarabine

      • an anthracyclines/anthracenedione ± an anti-metabolite, with or without growth factor or targeted therapy containing regimens.
    2. For adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; PIF is defined as AML refractory to one of the following less intensive regimens:

      • ≥ 2 but ≤ 4 cycles of Bcl-2 inhibitors in combination with azacitidine, decitabine, or low dose cytarabine
      • ≥ 2 but ≤ 4 cycles of gemtuzumab ozogamicin monotherapy
      • ≥ 6 but ≤ 8 cycles ivosidenib or enasidenib
    3. Leukemia in relapse after achieving CR

      • Early Relapse: disease recurrent within ≤ 6 month of documented remission
      • Late Relapse: disease recurrent within > 6 month of documented remission
      • Refractory-Relapse: refractory to ≥ 1 unsuccessful salvage attempts
  3. Patients with AML post hematopoietic stem cell transplant (HSCT) [permitted in Cohort Expansion Phase only] must meet the following criteria:

    • There must be histological confirmation of AML relapse after HSCT
    • Undergone allogeneic HSCT (alloSCT) > 90 days prior to enrollment from a match related donor, matched unrelated donor, cord blood donor, or haplo- identical donor
    • Off all immunosuppressive medications for a minimum of 2 weeks with the exception of physiologic doses (<10 mg) of corticosteroids
    • No history of Grade ≥ 3 veno-occlusive disease, or active graft versus host disease
  4. Patients with known central nervous system (CNS) involvement with AML are eligible if they have been treated and cerebrospinal fluid is clear for at least 2 weeks prior to enrollment into the study. CNS therapy (radiotherapy or chemotherapy) should continue as medically indicated during the study treatment.
  5. Patients with extramedullary disease are permitted if bone marrow blast count is >5%
  6. Adequate organ function as defined in the protocol
  7. Life expectancy >12 weeks
  8. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2 at screening


  1. Circulating blast count >30,000/µL by morphology or flow cytometry (cytoreductive therapies such as leukapheresis or hydroxyurea are allowed)
  2. Uncontrolled or untreated bacterial, fungal, or viral infections, including HIV, Hepatitis B or C infection, or uncontrolled infection of any etiology
  3. Uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiogram (ECG) suggestive of acute ischemia or active conduction system abnormalities
  4. Severe renal impairment, defined as creatinine clearance <40 mL/min
  5. New progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that have not been evaluated with bronchoscopy. Infiltrates attributed to infection must be stable/improving after 1 week of appropriate therapy (4 weeks for presumed or proven fungal infections).
  6. Known hypersensitivity to one or more of the study agents
  7. Received any investigational drugs within the 14 days prior to the first dose of fludarabine (wash-out period of at least 5 half-lives from the last dose of any investigational therapy prior to screening period or 14 days, whichever is longer)
  8. Pregnant or nursing (lactating) women
  9. Any condition that, in the opinion of the Investigator, would prevent the participant from consenting to or participating in the study


  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.


  • You have certain types of non-cancer medical conditions.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria.

Ask your doctor if this trial could be right for you.

Participating hospitals

Recruiting hospitals

InformationTell us if you find this trial availability is not accurate.Report inaccuracy

Get Support


Cancer Connect

You might find it helpful to speak to someone who has 'been there before'. Our Cancer Connect program can provide one-on-one phone support from someone who understands what you're going through and has clinical trials experience.

Learn more


Cancer Council’s cancer nurses

If you need cancer information and practical support for yourself, a carer, family or friend, contact Cancer Council’s experienced cancer nurses on 131120.

Learn more


Information for family, friends and carers

When you are considering a cancer clinical trial, it is a good idea to discuss it with your family, friends or carers.

Learn more

Victorian Cancer Registry Victorian Government

The Victorian Cancer Trials Link is supported by the Victorian Government through the Victorian Cancer Agency.


Cancer Council Victoria would like to acknowledge the traditional custodians of the land on which we live and work. We would also like to pay respect to the elders past and present and extend that respect to all other Aboriginal people.